cardiovascular disease
-
Pharma, Artificial Intelligence, BioPharma
Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
-
Startup Magnet Biomedicine Attracts $50M to Expand Scope of Molecular Glue Drugs
Magnet Biomedicine builds on decades of molecular glue research from its scientific co-founder, Harvard University Professor Stuart Schreiber. The startup is developing drugs that take these glues beyond the biotech industry’s current focus on targeted protein degradation.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
-
Consumer / Employer, Health Tech
Hims & Hers Dips Into Men’s Cardiovascular Health
Hims & Hers can now provide treatment to men for cardiovascular issues, the company recently announced. This treatment combines sexual health and heart health together in a single pill.
-
Novartis Pays Ionis $60M to Expand Alliance on a Hot Target for Cardio Drugs
Novartis and Ionis Pharmaceuticals, already partners in cardiovascular disease R&D, are expanding their alliance to see if they can develop a next-generation therapy offering efficacy and dosing advantages. But competitors are already in the mix with programs addressing the same cardiovascular disease target.
-
Amarin Restructures, Charting Course That Braces for Generic Competition
The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.
-
Eli Lilly Puts Up $60M for In Vivo Gene-Editing Med for Cardiovascular Disease
Eli Lilly’s partnership with Verve Therapeutics covers the development of a preclinical therapy addressing a protein associated with cardiovascular disease risk. The in vivo gene-editing therapy is a potential one-time treatment.
-
Devices & Diagnostics, Health Tech
Eko Launches Heart Disease Detection Platform CEO Calls ‘Shazam for Heartbeats’
Eko recently launched an AI-powered software that its CEO describes as “Shazam for heartbeats.” The platform connects with Eko’s digital stethoscopes and identifies whether or not a patient’s heart sounds are indicative of disease.
-
Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device
A new treatment under development by HeartPoint Global seeks to provide a minimally invasive and cheaper alternative to current treatments for pulmonary arterial hypertension.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Devices & Diagnostics, Health Tech, SYN
Abbott Enters TAVI Device Market Dominated by Edwards, Medtronic
Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.
-
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
Amgen posted positive Phase 2 data for olpasiran, further building the case for the drug’s blockbuster potential in heart disease as it proceeds to a pivotal test. Arrowhead Pharmaceuticals, which originally developed olpasiran and licensed it to the big pharma company, is cashing in now by selling its royalty rights to the molecule.
-
MedCity Influencers, Health Tech
Why better heart health worldwide is now within reach
By placing the power to detect atrial fibrillation into the hands of 6 billion global smartphone users, validation of further physiological parameters will be expedited and the subsequent adoption of this technology into DTx will enable the low-cost tools required to remove barriers to care and improve heart health across the globe.
-
MedCity Influencers, Community
Health equity is the solution to rising heart disease deaths
A better coronary artery stent cannot help a patient who cannot afford it, does not know they need it, doesn’t have a doctor who can make a diagnosis and identify that need. To help these patients, we urgently need to look at health equity.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Novartis turns to algorithms developer Anumana to apply AI to cardio conditions
Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.
-
Artificial Intelligence, BioPharma
SoftBank leads Dewpoint’s $150M round as multiple programs march toward clinic
Dewpoint is developing drugs targeting biomolecular condensates, tiny droplets in cells that contain proteins and nucleic acids. Dysfunction of these organelles can play a role in a wide range of diseases, including neurodegenerative disorders and cardiovascular disease.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
